Lactogenesis After Early Postpartum Use of the Contraceptive Implant
Authors:
- Shawn E. GurtcheffSGShawn E. Gurtcheff
- David K. TurokDTDavid K. Turok
- Greg StoddardGSGreg Stoddard
- Patricia A. MurphyPMPatricia A. Murphy
- Mark GibsonMGMark Gibson
- Kirtly P. JonesKJKirtly P. Jones
- 1 May 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 117 (5) , 1114-1121
Abstract
To evaluate lactogenesis after early postpartum insertion of the etonogestrel contraceptive implant. Healthy peripartum women with healthy, term newborns who desired the etonogestrel implant for contraception were randomly assigned to early (1-3 days) or standard (4-8 weeks) postpartum insertion. The primary outcomes, time to lactogenesis stage II and lactation failure, were documented by a validated measure. The noninferiority margin for the mean difference in time to lactogenesis stage II was defined as 8 additional hours. Secondary data (device continuation and contraceptive use, breast milk analysis, supplementation rates, side effects, and bleeding patterns) were collected at periodic intervals for 6 months. Sixty-nine women were enrolled. Thirty-five were randomly assigned to early insertion and 34 to standard insertion. There were no statistically significant differences between the groups in age, race, parity, mode of delivery, use of anesthesia, or prior breastfeeding experience. Early insertion was demonstrated to be noninferior to standard insertion in time to lactogenesis stage II (early: [mean±standard deviation] 64.3±19.6 hours; standard: 65.2±18.5 hours, mean difference, -1.4 hours, 95% confidence interval [CI] -10.6 to 7.7 hours). Early insertion was also demonstrated to be noninferior to standard insertion in incidence of lactation failure (1/34 [3%] in the early insertion group, 0/35 [0%] in the standard insertion group [risk difference, 0.03, 95% CI -0.02 to 0.08]). Use of formula supplementation was not significantly different between the groups. Milk composition at 6 weeks was not significantly different between the groups. Breastfeeding outcomes were similar in women who underwent early compared with standard postpartum insertion of the etonogestrel implant. ClinicalTrials.gov, www.clinicaltrials.gov, NCT00847587.Keywords
This publication has 22 references indexed in Scilit:
- Progestogen-only contraceptive use among breastfeeding women: a systematic reviewContraception, 2010
- Effects of birth spacing on maternal health: a systematic reviewAmerican Journal of Obstetrics and Gynecology, 2007
- Effects of the etonogestrel-releasing implant Implanon® and a nonmedicated intrauterine device on the growth of breast-fed infantsContraception, 2006
- Barriers to intrauterine device insertion in postpartum womenContraception, 2005
- Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrelContraception, 2005
- Breastfeeding and the Use of Human MilkPediatrics, 2005
- Effects of the etonogestrel-releasing contraceptive implant (Implanon®) on parameters of breastfeeding compared to those of an intrauterine deviceContraception, 2000
- Effect of the Interval between Pregnancies on Perinatal OutcomesNew England Journal of Medicine, 1999
- Premature introduction of progestin-only contraceptive methods during lactationContraception, 1997
- Use of norplant contraceptive implants in the immediate postpartum period: Safety and toleranceAmerican Journal of Obstetrics and Gynecology, 1995